Drug Trial Radar · NCT04721548
Treatment of Androgenetic Alopecia in Men for 24 Weeks
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
Mar 2, 2023
Primary completion
Mar 6, 2024
Study completion Mar 6, 2024
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Conditions
- Alopecia
Interventions
Minoxidil Topical FoamDrug
Apply 1 mL of solution twice a day.
PlaceboDrug
1 mL of solution twice a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in terminal thread density in the target area determined 180 (±3) days after the start of treatment compared to baseline density.Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eurofarma Laboratorios S.A
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.